Brainstorm Cell Therapeutics (NASDAQ:BCLI) Hits New 1-Year High – Still a Buy?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s stock price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $689.39 and last traded at $689.39, with a volume of 650492 shares. The stock had previously closed at $0.60.

Brainstorm Cell Therapeutics Stock Performance

The company has a market capitalization of $7.61 billion, a price-to-earnings ratio of -205.19 and a beta of 0.59. The stock’s fifty day simple moving average is $0.59 and its two-hundred day simple moving average is $0.69.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Gunderson Capital Management Inc. purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,950 shares of the biotechnology company’s stock, valued at approximately $29,000. Gunderson Capital Management Inc. owned 0.26% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).